Cytosorbents (NASDAQ:CTSO) Rating Reiterated by HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $1.00 price objective on the medical research company’s stock. HC Wainwright’s price target would indicate a potential upside of 14.69% from the stock’s current price.

Separately, StockNews.com began coverage on shares of Cytosorbents in a research note on Thursday, May 2nd. They set a “hold” rating for the company.

Cytosorbents Stock Down 6.5 %

CTSO opened at $0.87 on Tuesday. The stock’s fifty day moving average is $0.91 and its 200-day moving average is $1.12. Cytosorbents has a one year low of $0.78 and a one year high of $4.29. The company has a market capitalization of $47.35 million, a PE ratio of -1.36 and a beta of 0.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The firm had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. On average, equities analysts predict that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently modified their holdings of the stock. Key Client Fiduciary Advisors LLC raised its holdings in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares during the period. Chicago Partners Investment Group LLC increased its holdings in Cytosorbents by 84.0% in the third quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock worth $67,000 after buying an additional 16,598 shares during the last quarter. Raymond James & Associates bought a new position in Cytosorbents during the fourth quarter valued at approximately $56,000. Sargent Investment Group LLC lifted its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its position in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.